References
- 1. Beyreuther K., Biesalski H.K., Fernstrom J.D., Grimm P. Consensus meeting: monosodium Glutamate - an update. Eur J Clin Nutr., 2007; 61(3):304-13.
- 2. Mencinicopschi Gh. Biblia alimentara (Dietary Bible), Edit. Litera International, Bucharest, Romania, 2011: 94-95
- 3. Guo Y., Wang H.L., Xiang X.H., Zhao Y. The role of glutamate and its receptors in mesocorticolimbic dopaminergic regions in opioid addiction, Neurosci. and Biobehav. Reviews, 2009; (33) 864-873.
- 4. Buzescu A., Cristea A.N., Avram L., Chiriță C. Experimental Study On The Addictive Behavior Induced By Dietary Glutamic Acid. Practica Medicală, 2013;4(32): 229-233.
- 5. Cotman C.W., Kahle J.S., Miller S.E. Excitatory aminoacid neurotransmission. In Psychopharmacology: The Fourth Generation of Progress (Bloom F.E., Kupfer D.J.), Raven Press, New York, 1995:75-95.
- 6. Cortese B.M., Phan, K.L. The role of glutamate in anxiety and related disorders. CNS spectr., 2005; 10(10):820.
- 7. Simon AB, Gorman JM. Advances in the treatment of anxiety: targeting glutamate. NeuroRx., 2006; 3(1):57-68.
- 8. Letizia B., Maricla T., Sara C., Alessia L., Nicola Riccardo P., Rosita G., Paolo C. Magnetic resonance imaging volumes of the hippocampus in drug-naive patients with post-traumatic stress disorder without comorbidity conditions. J. Psych. Res., 2008; 42(9):752-62.
- 9. Cameron O.G., Thyer B.A. Symptom profiles of patients with dsm-hi anxiety disorders. Am. J. Psychiatry, 1986; 143(9):1132-7.
- 10. Amiel J.M., Mathew S.J. Glutamate and anxiety disorders. Curr. psychiatry rep., 2007; 9(4): 278-83.
- 11. Kuribara H., Stavinoha W., Maruyama Y. Behavioural pharmacological characteristics of honokiol, an anxiolytic agent present in extracts of magnolia bark, evaluated by an elevated plus-maze test in mice. J Pharm Pharmacol., 1998; 50(7):819-26.
- 12. Rodgers R.J., Shepherd J.K. Influence of prior maze experience on behaviour and response to diazepam in the elevated plus-maze and light/ dark tests of anxiety in mice. Psychopharm., 1993; 113(2):237-42
- 13. Prunell M., Escorihuela R.M., Fernández-Teruel A., Núnez J.F., Tobena A. Anxiolytic profiles of alprazolam and ethanol in the elevated plus-maze test and the early acquisition of shuttlebox avoidance. Pharmacol Res., 1994; 29(1):37-46.
- 14. Ciurea A.V., Edu F.V. Probleme de nocivitate în alimentele uzuale. Edit. Galaxia Gutenberg, Târgu-Lăpuş, 2011, 140-141.
- 15. Bush R.K., Taylor S.L. Adverse reactions to food and drug additives. In: Atkinson NF Jr, ed. Middleton’s Allergy: Principles and Practice. 7th ed. Philadelphia, Pa: Mosby Elsevier; 2008:chap 66.
- 16. Barkus C., McHugh S.B., Sprengel R., Seeburg P.H., Rawlins J.N.P., Bannerman D.M. Hippocampal NMDA receptors and anxiety: at the interface between cognition and emotion. Eur. J. Pharmacol., 2010; 626(1):49-56.
- 17. Bergami M., Rimondini R., Santi S., Blum R., Götz M., Canossa M. Deletion of TrkB in adult progenitors alters newborn neuron integration into hippocampal circuits and increases anxiety-like behavior. Proceedings of the National Academy of Sciences, 2008; 105(40):15570-5.
- 18. Ahnaou A., Dautzenberg F.M., Geys H., Imogai H., Gibelin A., Moechars D., Drinkenburg W.H. Modulation of group II metabotropic glutamate receptor (mGlu 2) elicits common changes in rat and mice sleep-wake architecture. Eur. J. Pharm., 2009; 603(1):62-72.
- 19. Kash S.F., Tecott, L.H., Hodge C., Baekkeskov S. Increased anxiety and altered responses to anxiolytics in mice deficient in the 65-kDa isoform of glutamic acid decarboxylase. Proceedings of the National Academy of Sciences, 1999; 96(4):1698-703.
- 20. Holmes A. Targeted gene mutation approaches to the study of anxietylike behavior in mice. Neuros. & Biobehavioral Rev., 2001; 25(3):261-73